Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ITCI
- Price
- -
- Stock movement down
- -0.05 (-0.04%)
- Company name
- Intra-Cellular Therapies Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 14.05B
- Ent value
- 13.76B
- Price/Sales
- 22.92
- Price/Book
- 12.27
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 42.18
- PEG
- -
- EPS growth
- -12.47%
- 1 year return
- 90.56%
- 3 year return
- 29.46%
- 5 year return
- 53.39%
- 10 year return
- 17.34%
Last updated: 2025-09-12
DIVIDENDS
ITCI does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 22.92 |
| Price to Book | 12.27 |
| EV to Sales | 22.45 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 106.52M |
| EPS (TTM) | -0.82 |
| FCF per share (TTM) | -0.59 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 612.92M |
| Gross profit (TTM) | 565.66M |
| Operating income (TTM) | -121.62M |
| Net income (TTM) | -86.37M |
| EPS (TTM) | -0.82 |
| EPS (1y forward) | 3.13 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 92.29% |
| Operating margin (TTM) | -19.84% |
| Profit margin (TTM) | -14.09% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 464.31M |
| Net receivables | 145.61M |
| Total current assets | 1.27B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 16.02M |
| Total assets | 1.32B |
| Accounts payable | 10.34M |
| Short/Current long term debt | 17.71M |
| Total current liabilities | 166.11M |
| Total liabilities | 179.62M |
| Shareholder's equity | 1.14B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -62.16M |
| Capital expenditures (TTM) | 750.00K |
| Free cash flow (TTM) | -62.91M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -7.54% |
| Return on Assets | -6.52% |
| Return on Invested Capital | -7.49% |
| Cash Return on Invested Capital | -5.46% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ITCI | S&P500 | |
| Current price drop from All-time high | -0.04% | -8.48% |
| Highest price drop | -87.64% | -56.47% |
| Date of highest drop | 1 Oct 2019 | 9 Mar 2009 |
| Avg drop from high | -39.32% | -10.99% |
| Avg time to new high | 40 days | 12 days |
| Max time to new high | 1585 days | 1805 days |
COMPANY DETAILS
Marketcap
14.05B
Marketcap category
Large-cap
Description
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Employees
860
Investor relations
-
SEC filings
CEO
Sharon Mates
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner